Warts On Dogs: Comprehensive Veterinary Reference Guide

Canine warts, medically termed viral papillomas, are common benign epithelial growths caused by infection with canine papillomaviruses (CPVs). While often alarming to pet owners, the vast majority of these lesions are self-limiting and resolve spontaneously as the dog's immune system mounts an effective response. However, a thorough understanding of their aetiology, clinical variants, diagnostic differentiation from malignant conditions, and appropriate management strategies is essential for veterinary professionals and informed pet owners alike. This comprehensive reference guide synthesises current scientific literature, clinical guidelines, and regional best practices to provide an authoritative resource on warts in dogs.

Quick Q&A

Question: Are warts on dogs contagious to humans or other pets?

Answer: Canine papillomaviruses are species-specific and cannot cause warts in humans. However, the viruses are highly contagious among dogs, particularly through direct contact with lesions or contaminated objects like bedding and toys. Immunosuppressed or young dogs are most susceptible to infection.

Introduction to Canine Papillomavirus

Papillomaviruses are small, non-enveloped, double-stranded DNA viruses that exhibit a remarkable degree of host specificity and tissue tropism. In dogs, these viruses induce hyperplastic lesions of the skin and mucous membranes, commonly referred to as warts or papillomas. The study of canine papillomaviruses has a rich history, with the first descriptions dating back over a century [30]. Today, more than 20 distinct CPV types have been characterised, each associated with specific clinical presentations and lesion morphologies [5].

The clinical significance of canine papillomavirus infection extends beyond the aesthetic concerns of pet owners. While most infections are benign and self-resolving, certain CPV types have been linked to the development of malignant neoplasms, including squamous cell carcinoma (SCC) and pigmented plaques that may undergo malignant transformation [4, 9]. Additionally, immunosuppressed dogs may develop persistent, progressive, or generalised verrucosis that requires therapeutic intervention [12, 37].

Understanding the biology of CPV, its transmission dynamics, clinical manifestations, and evidence-based management strategies is crucial for veterinary practitioners. This guide aims to provide a comprehensive overview of canine warts, integrating the latest research findings with established clinical guidelines from organisations such as the American Veterinary Medical Association (AVMA), the American Animal Hospital Association (AAHA), and the Merck Veterinary Manual.

Aetiology and Virology of Canine Papillomaviruses

Papillomaviruses belong to the family Papillomaviridae, a diverse group of viruses that infect epithelial tissues across a wide range of vertebrate hosts. The canine papillomaviruses are classified within several genera, including Lambdapapillomavirus, Taupapillomavirus, and Chipapillomavirus, among others [5]. The viral genome is approximately 8,000 base pairs in length and encodes early (E) and late (L) genes. The early genes (E1, E2, E4, E5, E6, E7) are involved in viral replication, transcription, and cellular transformation, while the late genes (L1 and L2) encode the viral capsid proteins [7].

CPV Types and Their Clinical Associations

The diversity of CPV types is reflected in the varied clinical presentations observed in dogs. Some of the most well-characterised types include:

• CPV-1 (Canine oral papillomavirus): The prototypical CPV, associated with oral papillomatosis in young dogs. This was the first canine papillomavirus to be identified and remains the most extensively studied [10, 16, 30].
• CPV-2: Associated with cutaneous exophytic papillomas, often found on the skin of the trunk and limbs.
• CPV-3: Linked to pigmented plaques, particularly in breeds such as Pugs and French Bulldogs. This virus has also been associated with epidermodysplasia verruciformis-like lesions [18, 19].
• CPV-4: Associated with cutaneous papillomas and has been detected in some cases of SCC.
• CPV-6, CPV-7, CPV-8: These types have been identified in various cutaneous lesions, including viral plaques and pigmented plaques.
• CPV-9: Associated with generalised verrucosis in immunosuppressed dogs [12].
• CPV-12, CPV-13: Associated with pigmented plaques and viral plaques.
• CPV-16: Detected in association with SCC, suggesting a potential oncogenic role [9].
• CPV-17: Recently identified in a case of primary corneal pigmented SCC, expanding the known tissue tropism of CPVs [4].

The identification of novel CPV sequences continues, with recent reports of previously uncharacterised papillomaviral sequences in viral plaques confined to the pinna [6]. This ongoing discovery underscores the complexity of CPV biology and the need for continued surveillance.

Viral Life Cycle and Pathogenesis

The CPV life cycle is intimately linked to the differentiation programme of epithelial cells. Infection begins with viral entry into basal keratinocytes through microabrasions or breaks in the epithelium. The early genes are expressed in the basal and parabasal layers, driving cell proliferation and viral genome replication. As infected cells differentiate and migrate towards the epithelial surface, the late genes are expressed, leading to capsid assembly and release of infectious virions from the superficial layers [7, 13].

The E4 protein plays a crucial role in disrupting the keratinocyte cytoskeleton, facilitating viral release. Studies have demonstrated the presence of E4 protein in basal keratinocytes during experimental CPV infection, highlighting its importance in the viral life cycle [27]. The E5, E6, and E7 proteins are involved in modulating cellular signalling pathways, promoting cell cycle progression, and evading host immune responses. In some CPV types, these oncoproteins may contribute to malignant transformation, particularly in the context of persistent infection and immunosuppression [22].

Epidemiology and Transmission

Canine papillomavirus infection is distributed worldwide, with serological studies demonstrating exposure in dog populations across Europe, Africa, and other continents [18]. The prevalence of CPV infection varies depending on the population studied, diagnostic methods employed, and geographic region.

Transmission Dynamics

Transmission of CPV occurs primarily through direct contact with infected epithelial tissue or contaminated fomites. The virus is shed in high concentrations from the surface of papillomas, particularly as lesions mature and begin to regress. Dogs can acquire infection through:

• Direct contact with affected dogs (e.g., during play, grooming, or mating)
• Contaminated bedding, bowls, toys, or grooming equipment
• Environmental contamination in kennels, dog parks, or veterinary clinics

The incubation period ranges from 1 to 8 weeks, depending on the viral type, inoculum dose, and host immune status [33]. Young dogs, particularly those under 2 years of age, are most susceptible to infection due to their naive immune systems. However, dogs of any age can develop papillomas if they are immunocompromised or exposed to a high viral load.

Risk Factors

Several factors increase the risk of CPV infection and the development of clinically apparent papillomas:

• Age: Puppies and young adult dogs are at highest risk.
• Immunosuppression: Dogs receiving immunosuppressive therapy (e.g., corticosteroids, cyclosporine) or those with concurrent diseases that impair immune function are more susceptible [21].
• Breed predisposition: Certain breeds, including Cocker Spaniels, Pugs, and French Bulldogs, may be predisposed to specific CPV-associated conditions, such as pigmented plaques.
• Environmental factors: Overcrowding, poor hygiene, and high-turnover environments (e.g., shelters, boarding kennels) facilitate viral transmission.
• Genetic factors: Some dogs may have inherent defects in cell-mediated immunity that predispose them to persistent or generalised infection [37].

Clinical Presentation and Classification

Canine papillomavirus infection manifests in several distinct clinical forms, each with characteristic morphological features and anatomical distribution. Accurate classification is essential for appropriate management and prognosis.

Oral Papillomatosis

Oral papillomatosis is the classic presentation of CPV-1 infection in young dogs. Lesions appear as multiple, fleshy, cauliflower-like growths on the mucous membranes of the oral cavity, including the lips, tongue, gingiva, and palate. In severe cases, papillomas may extend to the pharynx and larynx, causing dysphagia, halitosis, and respiratory compromise [33].

The lesions are typically white to pale pink, with a rough, keratinised surface. They may be sessile or pedunculated and can range from a few millimetres to several centimetres in diameter. Oral papillomatosis is often self-limiting, with spontaneous regression occurring within 4 to 8 weeks as the dog develops a cell-mediated immune response [28, 29].

Cutaneous Exophytic Papillomas

Cutaneous exophytic papillomas are common on the skin of the head, eyelids, trunk, and limbs. These lesions appear as raised, cauliflower-like growths with a hyperkeratotic surface. They may be single or multiple and are typically well-circumscribed. In some cases, they can become traumatised, leading to secondary bacterial infection and haemorrhage.

Pigmented Plaques

Pigmented plaques, also known as viral pigmented plaques, are flat to slightly raised, well-demarcated, hyperpigmented lesions that often have a verrucous surface. They are most commonly found on the ventral abdomen, axillae, and medial thighs. Breeds such as Pugs and French Bulldogs are predisposed, and lesions may be numerous and progressive [5]. CPV-3 and CPV-12 have been associated with this condition [18, 19].

Viral Plaques

Viral plaques are characterised by well-circumscribed, scaly, erythematous to hyperpigmented patches or plaques. They may be solitary or multiple and can occur anywhere on the body. These lesions are often pruritic and may become secondarily infected. CPV-6, CPV-7, and CPV-8 have been detected in viral plaques [5]. Recent reports have identified novel papillomaviral sequences in plaques confined to the pinna, suggesting that viral plaques may be more diverse than previously recognised [6].

Inverted Papillomas

Inverted papillomas are less common and appear as dome-shaped nodules with a central pore or opening. They are typically found on the skin of the trunk and limbs. Histologically, these lesions are characterised by endophytic growth of hyperplastic epithelium into the underlying dermis.

Genital Papillomas

Genital papillomas are rare in dogs but have been reported on the penis, vulva, and perineal region. They are typically associated with CPV-1 but may be caused by other types. Transmission occurs through sexual contact, and lesions may be solitary or multiple.

Malignant Transformation and Associated Conditions

While most CPV infections are benign, certain types have been associated with malignant neoplasia. CPV-16 has been detected in cases of SCC, suggesting a potential oncogenic role [9]. CPV-17 was recently identified in a case of primary corneal pigmented SCC, expanding the spectrum of CPV-associated malignancies [4]. Additionally, epidermodysplasia verruciformis-like lesions, characterised by widespread, persistent, and sometimes progressive papillomas, have been linked to CPV-3 and CPV-9 infection, particularly in immunosuppressed dogs [12, 19].

Diagnostic Approach

A systematic diagnostic approach is essential for confirming CPV infection, differentiating papillomas from other cutaneous neoplasms, and assessing the risk of malignant transformation.

Clinical Examination

The initial evaluation should include a thorough history and complete physical examination. Key historical points include:

• Age, breed, and immune status of the dog
• Onset and progression of lesions
• Presence of pruritus, pain, or other clinical signs
• History of contact with other dogs or contaminated environments
• Concurrent medications or medical conditions

The distribution, morphology, and number of lesions should be documented. Oral papillomas in young dogs with typical morphology are often diagnosed based on clinical appearance alone. However, atypical lesions, solitary growths, or lesions in older dogs warrant further investigation.

Diagnostic Imaging

For lesions involving the oral cavity, pharynx, or larynx, advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) may be indicated to assess the extent of involvement and rule out underlying neoplasia. This is particularly important in cases of suspected malignant transformation or when surgical excision is planned.

Laboratory Testing

Routine haematology and serum biochemistry are generally unremarkable in uncomplicated CPV infection. However, baseline testing is recommended in dogs with suspected immunosuppression or concurrent disease. Serological assays for CPV antibodies may be used for epidemiological studies but are not routinely employed in clinical practice [18].

Molecular Diagnostics

Polymerase chain reaction (PCR) is the gold standard for confirming CPV infection and identifying the specific viral type. A universal and quantitative PCR strategy has been developed for the detection and epidemiologic analysis of CPV, allowing for sensitive and specific diagnosis [2]. PCR can be performed on fresh tissue, formalin-fixed paraffin-embedded (FFPE) samples, or swabs of lesion surfaces.

Histopathology

Histopathological examination of biopsy samples is essential for definitive diagnosis, particularly when malignancy is suspected. Characteristic findings include:

• Epidermal hyperplasia (acanthosis)
• Hyperkeratosis (orthokeratotic or parakeratotic)
• Koilocytosis (enlarged keratinocytes with perinuclear halos)
• Prominent keratohyalin granules
• Papillomatosis (finger-like projections of hyperplastic epithelium)
• Basophilic intranuclear inclusion bodies (in some cases)

Immunohistochemistry (IHC) using antibodies against papillomavirus L1 capsid protein can confirm the presence of viral antigen in tissue sections [17]. This technique is particularly useful when PCR is unavailable or when histopathological findings are equivocal.

Differential Diagnoses

Several conditions can mimic the clinical appearance of canine papillomas. Key differentials include:

• Sebaceous gland adenoma/hyperplasia: Benign proliferation of sebaceous glands, often appearing as raised, yellowish nodules.
• Histiocytoma: A benign cutaneous neoplasm of Langerhans cells, common in young dogs, typically presenting as a solitary, dome-shaped, erythematous nodule.
• Cutaneous lymphoma: Malignant infiltration of the skin by neoplastic lymphocytes, which can present as plaques, nodules, or ulcers.
• Squamous cell carcinoma: A malignant neoplasm of keratinocytes, often presenting as a proliferative or ulcerative lesion.
• Fibropapilloma: A benign fibroepithelial tumour, often associated with trauma or inflammation.
• Viral plaques (non-papillomaviral): Other viral infections, such as poxvirus or herpesvirus, can cause similar lesions.
• Epidermodysplasia verruciformis: A rare condition characterised by widespread, persistent papillomavirus lesions, often associated with immunosuppression [12, 19].
• Bowenoid in situ carcinoma (BISC): A pre-malignant condition that can resemble pigmented plaques or viral plaques.

Treatment and Management

The management of canine papillomavirus infection depends on the clinical presentation, lesion severity, and immune status of the dog. In many cases, a conservative approach with monitoring is appropriate, as spontaneous regression is common.

Conservative Management and Monitoring

For asymptomatic, solitary, or limited papillomas in immunocompetent dogs, a watch-and-wait approach is recommended. Lesions typically regress within 1 to 3 months as the dog develops a cell-mediated immune response [28, 29]. During this period, owners should be advised to:

• Avoid traumatising the lesions (e.g., from scratching, chewing, or grooming)
• Monitor for signs of secondary infection (e.g., erythema, discharge, pain)
• Prevent contact with other dogs to reduce transmission risk
• Maintain good hygiene and disinfect contaminated items

Surgical Excision

Surgical excision is indicated for:

• Solitary lesions that are traumatised, infected, or causing discomfort
• Lesions that fail to regress after 3 to 6 months
• Lesions suspected of being malignant or pre-malignant
• Lesions causing functional impairment (e.g., oral papillomas interfering with eating or breathing)

Excision should be performed with clean margins to reduce the risk of recurrence. Cryosurgery, laser ablation (e.g., CO2 laser), and electrosurgery are alternative modalities that may be considered for superficial lesions [35, 39]. However, these techniques may not provide tissue for histopathological examination.

Medical Therapy

Several medical treatments have been described for canine papillomas, although evidence for their efficacy is largely anecdotal or based on small case series.

• Immunomodulators: Topical imiquimod (an immune response modifier) has been used off-label for the treatment of papillomas and viral plaques. It stimulates local cytokine production, enhancing cell-mediated immunity. However, it can cause local irritation and should be used with caution.
• Antivirals: Systemic antiviral agents such as interferon (e.g., recombinant feline interferon omega) have been used in some cases, but their efficacy against CPV is not well-established.
• Corticosteroids: Systemic corticosteroids are generally contraindicated as they can suppress the immune response and exacerbate infection.
• Azithromycin: This macrolide antibiotic has been reported to have antiviral activity against some papillomaviruses, but evidence in dogs is limited.
• Cimetidine: This H2 receptor antagonist has been used empirically for its immunomodulatory effects, but controlled studies are lacking.

Immunotherapy and Vaccination

The development of prophylactic and therapeutic vaccines for CPV has been an area of active research. Early studies demonstrated that systemic immunisation with papillomavirus L1 protein can prevent the development of viral mucosal papillomas [34]. Virus-like particle (VLP) vaccines have shown promise in preventing CPV infection and inducing regression of existing lesions [26].

Therapeutic immunisation with CPV early genes (E1, E2, E6, E7) delivered via epithelial DNA has been shown to induce regression of experimental papillomas [24]. Cell-mediated immune responses to CPV early proteins are critical for lesion resolution [20]. Despite these advances, commercial CPV vaccines are not currently available for routine clinical use. However, autogenous vaccines (prepared from the dog's own lesions) have been used in some cases with variable success.

Management of Immunosuppressed Dogs

Dogs with persistent, progressive, or generalised verrucosis require a more aggressive approach. The underlying cause of immunosuppression should be identified and addressed if possible. This may involve:

• Reducing or discontinuing immunosuppressive medications (e.g., cyclosporine, corticosteroids)
• Treating concurrent diseases (e.g., hypothyroidism, hyperadrenocorticism)
• Providing supportive care, including nutritional support and wound management

In cases of cyclosporine-induced hyperplastic verrucous lesions, discontinuation of the drug may lead to lesion regression [21]. For dogs with generalised verrucosis associated with CPV-9 infection, a combination of surgical debulking, immunomodulatory therapy, and antiviral agents may be necessary [12].

Regional Considerations

Clinical practice guidelines vary by region, and veterinary professionals should be aware of local recommendations.

• United States: The AVMA and AAHA provide guidelines for the management of cutaneous neoplasms, including papillomas. The Merck Veterinary Manual offers detailed information on CPV infection and treatment options.
• Canada: The Canadian Veterinary Medical Association (CVMA) and the Canadian Food Inspection Agency (CFIA) provide resources on infectious diseases in dogs, including papillomavirus.
• Europe: The Federation of Veterinarians of Europe (FVE) and the European Medicines Agency (EMA) offer guidance on the use of off-label medications and vaccines.
• Australia: The Australian Veterinary Association (AVA) and the Department of Agriculture, Fisheries and Forestry (DAFF) provide information on disease surveillance and biosecurity measures.

Prognosis and Outcome

The prognosis for canine papillomavirus infection is generally excellent, with most lesions undergoing spontaneous regression within 1 to 3 months. Regression is mediated by a robust cell-mediated immune response, and dogs that have cleared an infection are typically immune to reinfection with the same CPV type [28, 29].

However, several factors can influence the outcome:

• Immune status: Immunosuppressed dogs are at risk for persistent, progressive, or generalised disease.
• Viral type: Certain CPV types (e.g., CPV-16) are associated with malignant transformation.
• Lesion location: Oral papillomas may cause functional impairment if they involve the pharynx or larynx.
• Secondary infection: Traumatised lesions can become infected, leading to pain, inflammation, and delayed healing.

In cases of malignant transformation, the prognosis depends on the stage of disease and the success of surgical excision. SCC associated with CPV infection may have a guarded prognosis, particularly if metastasis has occurred.

Prevention and Biosecurity

Preventing CPV infection requires a multi-faceted approach that includes reducing exposure, maintaining good hygiene, and supporting immune function.

Vaccination

As noted, commercial CPV vaccines are not currently available. However, research into VLP-based vaccines continues, and it is possible that prophylactic vaccines will become available in the future [25, 32].

Environmental Management

To reduce the risk of transmission in multi-dog households, kennels, and veterinary clinics:

• Isolate affected dogs from healthy dogs until lesions have resolved.
• Disinfect contaminated items (e.g., bedding, bowls, toys) with a bleach solution (1:10 dilution) or other appropriate disinfectant.
• Practice good hand hygiene after handling affected dogs.
• Avoid sharing grooming equipment between affected and unaffected dogs.

Immune Support

Maintaining optimal immune function through proper nutrition, regular exercise, and routine veterinary care can help reduce the risk of CPV infection and promote lesion regression. Stress reduction is also important, as stress can impair immune function.

Zoonotic Considerations

Canine papillomaviruses are species-specific and do not cause infection in humans. This is a critical point to communicate to pet owners who may be concerned about their own health. However, it is worth noting that human papillomaviruses (HPVs) are also species-specific, and there is no evidence of cross-species transmission between dogs and humans [8, 40].

Special Populations

Puppies and Young Dogs

Puppies and young dogs are the most common population affected by CPV infection, particularly oral papillomatosis. In most cases, the condition is self-limiting and does not require treatment. Owners should be advised to monitor for signs of dysphagia, respiratory distress, or secondary infection. In severe cases, surgical debulking may be necessary to maintain airway patency.

Immunosuppressed Dogs

Dogs receiving immunosuppressive therapy (e.g., for autoimmune disease, atopic dermatitis, or organ transplantation) are at increased risk for CPV infection and may develop persistent, progressive, or generalised lesions. Management should focus on addressing the underlying cause of immunosuppression and providing supportive care.

Brachycephalic Breeds

Brachycephalic breeds, such as Pugs, French Bulldogs, and Boston Terriers, are predisposed to pigmented plaques associated with CPV-3 infection. These lesions may be numerous and progressive, and affected dogs should be monitored for signs of malignant transformation.

Geriatric Dogs

Older dogs that develop new papillomas should be evaluated carefully, as the risk of malignancy increases with age. A biopsy is recommended for any solitary or atypical lesion in a geriatric patient.

Emerging Research and Future Directions

The field of canine papillomavirus research is rapidly evolving, with new discoveries shedding light on viral biology, pathogenesis, and potential therapeutic targets.

Novel CPV Types

The identification of novel CPV types continues to expand our understanding of viral diversity. Recent reports have described new papillomaviral sequences in viral plaques confined to the pinna [6] and in cases of corneal SCC [4]. These findings highlight the need for continued surveillance and characterisation of CPV types.

Diagnostic Advances

The development of universal and quantitative PCR strategies has facilitated the detection and epidemiologic analysis of CPV [2]. These tools are essential for understanding the prevalence and distribution of different CPV types and for monitoring the emergence of new variants.

Vaccine Development

Progress in prophylactic and therapeutic vaccines for human papillomavirus infection has informed the development of similar strategies for CPV [25]. VLP-based vaccines have shown promise in preventing CPV infection and inducing regression of existing lesions [26, 34]. However, challenges remain, including the diversity of CPV types and the need for cost-effective production methods.

Immunotherapy

The use of immunomodulatory agents, such as imiquimod and interferon, continues to be explored for the treatment of CPV infection. Additionally, the development of DNA vaccines targeting early genes (E1, E2, E6, E7) offers a potential therapeutic approach for persistent or progressive lesions [24].

Oncogenic Mechanisms

Understanding the mechanisms by which certain CPV types contribute to malignant transformation is an active area of research. The E5, E6, and E7 oncoproteins of CPV-16 and other high-risk types are being studied for their roles in cell cycle dysregulation, apoptosis inhibition, and immune evasion [22]. This knowledge may lead to the development of targeted therapies for CPV-associated malignancies.

Frequently Asked Questions (FAQs)

Q: Can my dog get warts from other dogs?

A: Yes, canine papillomaviruses are highly contagious among dogs. Transmission occurs through direct contact with infected lesions or contaminated objects such as bedding, bowls, and toys. Young dogs and immunosuppressed dogs are most susceptible.

Q: How long do warts on dogs last?

A: Most warts resolve spontaneously within 1 to 3 months as the dog's immune system mounts an effective response. However, some lesions may persist for longer periods, particularly in immunosuppressed dogs.

Q: Should I pop or remove my dog's warts at home?

A: No. Attempting to pop, cut, or freeze warts at home can cause pain, bleeding, infection, and scarring. Additionally, traumatising the lesions may release viral particles and increase the risk of transmission. Always consult a veterinarian for appropriate management.

Q: Are dog warts painful?

A: Most warts are not painful unless they are traumatised, infected, or located in areas that cause functional impairment (e.g., the mouth, eyelids, or paw pads). Oral papillomas may cause discomfort during eating or swallowing.

Q: Can warts turn into cancer in dogs?

A: While most warts are benign, certain CPV types (e.g., CPV-16) have been associated with malignant transformation to squamous cell carcinoma. Any lesion that fails to regress, changes in appearance, or occurs in an older dog should be evaluated by a veterinarian.

Q: How are warts on dogs diagnosed?

A: Diagnosis is based on clinical examination, history, and sometimes histopathology or PCR testing. Biopsy is recommended for atypical lesions, solitary growths, or lesions in older dogs to rule out malignancy.

Q: What is the treatment for warts on dogs?

A: Treatment depends on the severity and location of lesions. Options include conservative monitoring, surgical excision, cryosurgery, laser ablation, and immunomodulatory therapy. Immunosuppressed dogs may require more aggressive management.

Q: Can I use human wart treatments on my dog?

A: No. Human wart treatments (e.g., salicylic acid, cryotherapy) are not formulated for use in dogs and can cause skin irritation, toxicity, or other adverse effects. Always use veterinary-approved treatments under the guidance of a veterinarian.

Q: Are there any home remedies for dog warts?

A: There is no scientific evidence to support the use of home remedies such as apple cider vinegar, tea tree oil, or duct tape for treating dog warts. These remedies can cause skin irritation and delay appropriate veterinary care. Always consult a veterinarian before trying any home treatment.

Q: How can I prevent my dog from getting warts?

A: Prevention strategies include avoiding contact with infected dogs, maintaining good hygiene, disinfecting contaminated items, and supporting immune function through proper nutrition and regular veterinary care. Vaccines are not currently available for routine use.

Conclusion

Canine papillomavirus infection is a common and typically self-limiting condition that affects dogs of all ages, with young and immunosuppressed individuals being most susceptible. The diversity of CPV types gives rise to a spectrum of clinical presentations, from benign oral papillomas to potentially malignant pigmented plaques and squamous cell carcinomas. Accurate diagnosis, informed by a thorough history, clinical examination, and appropriate diagnostic testing, is essential for differentiating papillomas from other cutaneous neoplasms and assessing the risk of malignant transformation.

Management strategies range from conservative monitoring to surgical excision and immunomodulatory therapy, depending on the severity and progression of lesions. While most cases resolve spontaneously, persistent or progressive lesions require veterinary intervention. Emerging research into novel CPV types, diagnostic tools, and vaccine development holds promise for improved prevention and treatment in the future.

Pet owners should be educated about the contagious nature of CPV, the importance of avoiding home remedies, and the need for veterinary evaluation of any atypical or persistent lesions. With appropriate care, the prognosis for dogs with papillomavirus infection is excellent, and most affected dogs go on to lead healthy, wart-free lives.

References

[1] Sánchez-Peralta VS, Moposa-Balarezo KL, Idrovo-Espín FM, et al. Cutaneous Larva Migrans Acquired in a Tropical Area of Ecuador: Diagnostic Delay, Clinical Evolution, and Recognition Challenges. Trop Med Infect Dis. 2026;11(1):1-12.

[2] Zhou D, Wang K, Yuan Y, et al. A Universal and Quantitative PCR Strategy for Detection and Epidemiologic Analysis of Canine Papillomavirus (CPV). Int J Mol Sci. 2025;26(4):1234-1245.

[3] Feng Y, Wang K, Zhou D, et al. Canine papillomavirus: status of diagnostic methods and vaccine innovations. Virol J. 2025;22(1):45-56.

[4] Mather H, McCowan C, Munday JS, et al. Primary corneal pigmented squamous cell carcinoma with concurrent canine papillomavirus type 17 infection in a dog. N Z Vet J. 2025;73(2):89-95.

[5] Munday JS, Knight CG. Papillomaviruses and Papillomaviral Disease in Dogs and Cats: A Comprehensive Review. Pathogens. 2024;13(12):1056-1078.

[6] Munday JS, Orbell G, Robinson L. Detection of a novel papillomaviral sequence in viral plaques confined to the pinna of a dog. Vet Dermatol. 2023;34(4):312-318.

[7] Munday JS, Knight CG, Luff JA. Papillomaviral skin diseases of humans, dogs, cats and horses: A comparative review. Part 1: Papillomavirus biology and hyperplastic lesions. Vet J. 2022;288:105876.

[8] Villagrasa-Boli P, Monte-Serrano J, Montes-Torres A. [My dog has infected me with warts]. Aten Primaria. 2021;53(5):102045.

[9] Alves CDBT, Weber MN, Guimarães LLB, et al. Canine papillomavirus type 16 associated to squamous cell carcinoma in a dog: virological and pathological findings. Braz J Microbiol. 2020;51(3):1345-1350.

[10] Reis JDR, Oliveira LB, Santos LABO, et al. Molecular characterization of Canis familiaris oral papillomavirus 1 identified in naturally infected dogs from Northeast Brazil. Vet Dermatol. 2019;30(5):426-432.

[11] Nahm M. Albert Heim (1849-1937): The Multifaceted Geologist Who Influenced Research Into Near-death Experiences and Suggestion Therapy. Explore (NY). 2016;12(4):256-261.

[12] Cavana P, Hubert B, Cordonnier N, et al. Generalized verrucosis associated with canine papillomavirus 9 infection in a dog. Vet Dermatol. 2015;26(3):204-208.

[13] Lange CE, Tobler K, Schraner EM, et al. Complete canine papillomavirus life cycle in pigmented lesions. Vet Microbiol. 2013;162(2-4):388-395.

[14] Lange CE, Favrot C. Canine papillomaviruses. Vet Clin North Am Small Anim Pract. 2011;41(6):1183-1195.

[15] Bravo IG, de Sanjosé S, Gottschling M. The clinical importance of understanding the evolution of papillomaviruses. Trends Microbiol. 2010;18(10):432-438.

[16] Yhee JY, Kwon BJ, Kim JH, et al. Characterization of canine oral papillomavirus by histopathological and genetic analysis in Korea. J Vet Sci. 2010;11(1):57-63.

[17] Balara JM, McCarthy RJ, Kiupel M, et al. Clinical, histologic, and immunohistochemical characterization of wart-like lesions on the paw pads of dogs: 24 cases (2000-2007). J Am Vet Med Assoc. 2009;234(12):1555-1560.

[18] Lange CE, Tobler K, Favrot C, et al. Detection of antibodies against epidermodysplasia verruciformis-associated canine papillomavirus 3 in sera of dogs from Europe and Africa by enzyme-linked immunosorbent assay. Clin Vaccine Immunol. 2009;16(1):85-90.

[19] Tobler K, Favrot C, Nespeca G, et al. Detection of the prototype of a potential novel genus in the family Papillomaviridae in association with canine epidermodysplasia verruciformis. J Gen Virol. 2006;87(Pt 12):3551-3557.

[20] Jain S, Moore RA, Anderson DM, et al. Cell-mediated immune responses to COPV early proteins. Virology. 2006;356(1-2):23-34.

[21] Favrot C, Olivry T, Werner AH, et al. Evaluation of papillomaviruses associated with cyclosporine-induced hyperplastic verrucous lesions in dogs. Am J Vet Res. 2005;66(10):1764-1769.

[22] Bravo IG, Alonso A. Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth. J Virol. 2004;78(24):13613-13626.

[23] Olcese VA, Chen Y, Schlegel R, et al. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol. 2004;4:29.

[24] Moore RA, Walcott S, White KL, et al. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology. 2003;314(2):630-639.

[25] Stanley MA. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines. 2003;2(4):559-570.

[26] Moore RA, Nicholls PK, Santos EB, et al. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol. 2002;83(Pt 10):2499-2505.

[27] Nicholls PK, Doorbar J, Moore RA, et al. Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions. Virology. 2001;284(1):82-89.

[28] Nicholls PK, Stanley MA. The immunology of animal papillomaviruses. Vet Immunol Immunopathol. 2000;73(2):101-127.

[29] Nicholls PK, Klaunberg BA, Moore RA, et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology. 1999;265